Clinical trials: Attention Deficit Hyperactivity Disorder in Adults
Healthy Adult Participants
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult…
- Trial name
- NCT07486895
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD Predominantly Inattentive Type
Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
study objectives are to compare the efficacy, safety and tolerability of two doses of MG01CI (1400 mg and 700 mg) to Placebo for the treatment of symptoms in adults diagnosed with PI-ADHD.
- Trial name
- NCT01685281
- Testing
- Metadoxine (MG01CI)
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- Alcobra Ltd.
Attention Deficit Hyperactivity Disorder (ADHD)
Experimental Medicine in ADHD - Cannabinoids
Adult patients with ADHD commonly report an improvement in behavioural symptoms when using cannabis with some reporting a preference towards cannabis over their ADHD stimulant medication.
- Trial name
- EMA-C (NCT02249299)
- Testing
- Sativex Oromucosal Spray
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College London
Attention-Deficit / Hyperactivity Disorder
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01357993
- Testing
- JNS001
- Where
- 29 sites in Japan
- Volunteers
- 253 people
- Sponsor
- Janssen Pharmaceutical K.K.
Adult ADHD
Recollect the Game: A Novel Treatment for Executive Functioning Deficits in Adults With ADHD
Adults who have attention deficit hyperactivity disorder (ADHD) suffer from significant occupational, academic and social problems, many of which are believed to be a result of problems with executive functioning.
- Trial name
- NCT03437993
- Testing
- Recollect, the game, Tetris
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McMaster University
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD.
- Trial name
- NCT00152022
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
- Volunteers
- 412 people
- Sponsor
- Shire
Impulsive Behavior, Compulsive Disorder
Treating Impulsivity in Adults With Probiotics
A multicentre randomized double-blind placebo controlled parallel design (10 weeks) study investigating probiotic supplementation in highly impulsive adults (18-65 yrs; N=180).
- Conditions
- Impulsive Behavior, Compulsive Disorder, ADHD, Borderline Personality Disorder
- Trial name
- PROBIA (NCT03495375)
- Testing
- Treatment with a probiotic
- Where
- 3 sites in Germany, Hungary and 1 more
- Volunteers
- 180 people
- Sponsor
- Hospital Vall d'Hebron
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
This is a 12-week clinical trial evaluating the efficacy and safety of memantine hydrochloride (Namenda) in the treatment of executive function deficits (EFDs) in adults with Attention Deficit Hyperactivity Disorder (ADHD)…
- Trial name
- NCT01533493
- Testing
- Memantine Hydrochloride, OROS-Methylphenidate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder, Generalized Anxiety Disorder
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Other psychiatric disorders, including anxiety, often co-occur with adult ADHD; with 85% of ADHD patients having at least one other psychiatric condition.
- Conditions
- Attention Deficit Hyperactivity Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
- Trial name
- NCT03785223
- Testing
- Methylphenidate Hydrochloride Controlled-Release Capsules
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- McMaster University
Attention-Deficit Hyperactivity Disorder Symptoms, Attention-Deficit Hyperactivity Disorder
Tailored Yoga Therapy for Attention-deficit Hyperactivity Disorder
This study will explore the feasibility, acceptability, and potential benefits of a group-based tailored yoga programme designed for adults experiencing symptoms of attention-deficit hyperactivity disorder.
- Trial name
- Yoga4ADHD (NCT07541820)
- Testing
- Tailored yoga therapy., Functional movement.
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College London
Attention-Deficit/Hyperactivity Disorder, ADHD
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00429091
- Testing
- ABT-894, atomoxetine
- Where
- 22 sites in United States
- Volunteers
- 243 people
- Sponsor
- Abbott
Adult Attention Deficit Hyperactivity Disorder
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
This is a single-site study. One purpose of this trial is to extend the safety and efficacy evidence basis for Azstarys in adults with ADHD.
- Trial name
- NCT06000501
- Testing
- Serdexmethylphenidate/dexmethylphenidate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
Cerebrovascular Accident, Transient Ischemic Attack
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 January 2003 through 31…
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Trial name
- NCT00634439
- Testing
- atomoxetine, Stimulants, No intervention (general population)
- Where
- United States
- Volunteers
- 72,000 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
The purpose of this study is to a) assess the efficacy of omega-3 fatty acids in the treatment of Deficient Emotional Self-Regulation (DESR) among stimulant treated Attention Deficit Hyperactivity Disorder (ADHD) adults, b)…
- Trial name
- NCT01399827
- Testing
- ADHD Medication, Omega-3 Fatty Acids
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
ADHD
Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder
This research study is being done to examine how meditation and the relaxation response (RR) may change brain activity in attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- ADHD (NCT01404273)
- Testing
- Meditation/Relaxation Response Training
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Effects of a Novel Neurofeedback Protocol on ADHD Subcomponents
Mounting evidence suggests that closed-loop brain-training, commonly known as neurofeedback (NFB), may represent a new therapeutic opportunity for patients with Attentional Deficit/Hyperactivity Disorder (ADHD), which manifests…
- Trial name
- NFB@HOME (NCT04408521)
- Testing
- NEUROFEEDBACK, CONTROL
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- University Hospital, Geneva
Attention Deficit Disorder With Hyperactivity
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT02951754
- Testing
- Immediate-release Methylphenidate
- Where
- Brazil
- Volunteers
- 600 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Attention Deficit/Hyperactivity Disorder(ADHD), Alcohol Use
Smartphone-based Intervention for Young Adults With ADHD
The primary goal of this clinical trial is to test if a smartphone-based intervention is feasible \& acceptable among young adults with ADHD who also engage in risky drinking behaviors.
- Trial name
- NCT07654205
- Testing
- Ecological Momentary Assessment for ADHD and Substance Use - Intervention Group, Ecological Momentary Assessment for ADHD & Substance Use - Control Group
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Traci Kennedy